# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $20 price target.
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(6.42) per share which beat the analyst consensus estimate of $...
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in t...